. . . "2022-85-7"@en . . "Flucytosine is excreted via the kidneys by means of glomerular filtration without significant tubular reabsorption. A small portion of the dose is excreted in the feces."@en . . "A fluorinated cytosine analog that is used as an antifungal agent. [PubChem]"@en . . "Rapidly and virtually completely absorbed following oral administration. Bioavailability 78% to 89%."@en . . "Yeast and other fungi"@en . . . . "For the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections)."@en . . "5-Fluorocytosin"@en . . . . . . "Flucytosin"@en . "Flucytosine"@en . . . "approved"@en . . . . . "Bernd Baasner, Erich Klauke, \"Process for the preparation of 5-fluorocytosine.\" U.S. Patent US4703121, issued September, 1961."@en . . . . "Ancobon (tn)"@en . "2.4 to 4.8 hours."@en . "Although the exact mode of action is unknown, it has been proposed that flucytosine acts directly on fungal organisms by competitive inhibition of purine and pyrimidine uptake and indirectly by intracellular metabolism to 5-fluorouracil. Flucytosine enters the fungal cell via cytosine permease; thus, flucytosine is metabolized to 5-fluorouracil within fungal organisms. The 5-fluorouracil is extensively incorporated into fungal RNA and inhibits synthesis of both DNA and RNA. The result is unbalanced growth and death of the fungal organism. It also appears to be an inhibitor of fungal thymidylate synthase."@en . . . . . . . . . " "@en . . . . . . . "5-FC"@en . . . "5-Flurocytosine"@en . "Oral, rat: LD₅₀ = >15 gm/kg."@en . . . . . "Fluocytosine"@en . . "28-31%"@en . "5-Fluorocytosine"@en . . "5-Fluorocystosine"@en . . "Flucytosine"@en . . . . . . . "Fluorcytosine"@en . . .